Evidence map›Paper›PMID 38608417›Full record

ArticleSchizophrenia research2024

The MATRICS consensus cognitive battery for the assessment of cognitive impairment in schizotypal personality disorder.

Katelyn N Challman, Daniel R Rosell, Deanna Barch, Harold W Koenigsberg, Philip D Harvey, Erin A Hazlett, M Mercedes Perez-Rodriguez, Antonia S New, Margaret McNamara McClure

Abstract read
In one paragraph

Article in Schizophrenia research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Aberrant effective connectivity during working memory performance in schizotypal personality disorder and schizophrenia: A spectrum approach.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Katelyn N ChallmanMental Illness Research, Education, and Clinical Center (MIRECC VISN 2), James J. Peters VA Medical Center, 130 W. Kingsbridge Road, Bronx, NY 10468, United States of America; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, United States of America.
Daniel R RosellDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, United States of America.
Deanna BarchWashington University in St. Louis, One Brookings Drive St. Louis, MO 63130, United States of America.
Harold W KoenigsbergMental Illness Research, Education, and Clinical Center (MIRECC VISN 2), James J. Peters VA Medical Center, 130 W. Kingsbridge Road, Bronx, NY 10468, United States of America; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, United States of America.
Philip D HarveyUniversity of Miami Health System, 1120 NW 14th St, Miami, FL 33136, United States of America.
Erin A HazlettMental Illness Research, Education, and Clinical Center (MIRECC VISN 2), James J. Peters VA Medical Center, 130 W. Kingsbridge Road, Bronx, NY 10468, United States of America; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, United States of America.
M Mercedes Perez-RodriguezDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, United States of America.
Antonia S NewDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, United States of America.
Margaret McNamara McClureMental Illness Research, Education, and Clinical Center (MIRECC VISN 2), James J. Peters VA Medical Center, 130 W. Kingsbridge Road, Bronx, NY 10468, United States of America; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, United States of America; Department of Psychological and Brain Sciences, Fairfield University, 1073 North Benson Road Fairfield, CT 06824, United States of America. Electronic address: margaret.mcnamara@mssm.edu.
Icahn School of Medicine at Mount Sinai · USMental Illness Research, Education and Clinical Centers · USFairfield University · USJames J. Peters VA Medical Center · USUniversity of Miami Health System · USWashington University in St. Louis · US

Funding

Longitudinal neuroimaging and neurocognitive assessment of risk and protective factors across the schizophrenia spectrumR01MH121411 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAZLETT, ERIN A., SZESZKO, PHILIP R · 2020 to 2024
$4.8M
A D1 Agonist for Working Memory Enhancement in the Schizophrenia SpectrumR01MH097799 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI NEW, ANTONIA S · 2013 to 2017
$2.5M
CSRD VA IK6 CX002700NIMH NIH HHS R01 MH097799NIMH NIH HHS R01 MH121411
6 · The paper itself

Abstract

Cognitive deficits are a core impairment across the range of schizophrenia (SZ) spectrum disorders, including schizotypal personality disorder (SPD). The MATRICS Consensus Cognitive Battery (MCCB) was developed to be a robust, specific, and valid cognitive assessment battery to assess cognition in clinical trials for treating cognitive impairments in SZ. Despite the similarity of cognitive impairments shown in SPD and SZ and the clear relevance of uniform assessment across a diagnostic spectrum, the MCCB has yet to be validated in SPD. As such, this is the first study to evaluate the sensitivity of the MCCB for the assessment of cognitive function in individuals with SPD. Participants were 30 individuals with SPD and 54 healthy controls (HC) assessed with the MCCB and supplemental neurocognitive assessments (Trails B, DOT test, Paced Auditory Serial Addition Test (PASAT), AX Continuous Performance Task (AX-CPT), and N-back). Individuals with SPD performed worse than HC participants on all MCCB subtests, as well as on converging supplemental tasks including Trails B, DOT test, PASAT, AX-CPT, and N-back. These results indicate that the MCCB was sensitive to cognitive impairment in SPD compared to controls. SPD participants demonstrate impairments similar to data of SZ participants within the literature, although to a slightly lesser degree of severity. Taken together, these results highlight the generalizability of using the MCCB across SZ spectrum diagnostic groups to assess cognition. Such findings allow for further comparison across disorders, greater understanding of the cognitive characteristics in the spectrum, and use of uniform assessment within cognitive intervention research.

Indexed as

Cognitive DysfunctionNeuropsychological TestsSchizotypal Personality DisorderAdultFemaleHumansMaleMiddle AgedYoung AdultCognitionFunctioningMATRICSSchizophrenia-spectrumSchizotypal personality disorder

Identifiers

PMID38608417
PMCPMC13196496
OpenAlexW4394733140

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.